Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

You may be eligible if

• 1. Histological confirmed non-small cell lung cancer (NSCLC), Stage IIIB or stage IV, between January 1, 2008 to December 31, 2011
• 2. Confirmed EGFR rare mutations (EGFR mutation except both exon 19 deletion and exon 21 L858R) using direct DNA sequencing
• 3. Experiences of treatment with EGFR TKIs.
• 4. at least one measurable and/or evaluable lesion according to RECIST criteria (version 1.1)